PDF(Pubmed)
Abstract：
The present study investigated the relationship between MSH3 and MSH6 genes in lung cancer patients. Genotyping of lung cancer patients and healthy controls was performed. Odds ratio values were calculated and survival analysis performed. Patients with mutant genotype (TT) for MSH6 polymorphism have 1.5-fold risk for the development of lung cancer (p = 0.03). For non-smokers, the mutant-type genotype had a threefold increased risk of lung cancer (p = 0.01). Patients administered with docetaxel and carbo/cisplatin and carrying GT genotype for MSH6 polymorphism, patients reported a decrease in median survival time (4.9 vs 9.13 months). MSH3 and MSH6 polymorphisms are involved in modulating the risk towards lung cancer. MSH6 polymorphism is associated with high mortality rate for patients undergoing cisplatin and docetaxel chemotherapy.
摘要：
本研究调查了肺癌患者MSH3和MSH6基因之间的关系。对肺癌患者和健康对照者进行基因分型。计算赔率比值并进行生存分析。具有MSH6多态性突变基因型（TT）的患者发生肺癌的风险为1.5倍（p=0.03）。对于非吸烟者来说，突变型基因型的肺癌风险增加了3倍(p=0.01).服用多西他赛和碳/顺铂并携带MSH6多态性GT基因型的患者，患者报告中位生存时间减少(4.9个月vs9.13个月).MSH3和MSH6多态性参与调节患肺癌的风险。MSH6多态性与接受顺铂和多西他赛化疗的患者的高死亡率相关。
